{"id":4415,"date":"2025-10-07T16:00:35","date_gmt":"2025-10-07T20:00:35","guid":{"rendered":"https:\/\/www.gensight-biologics.com\/gensight-biologics-publie-sa-situation-de-tresorerie-au-30-septembre-2025\/"},"modified":"2026-09-24T00:05:39","modified_gmt":"2026-09-24T04:05:39","slug":"gensight-biologics-publie-sa-situation-de-tresorerie-au-30-septembre-2025","status":"publish","type":"post","link":"https:\/\/www.gensight-biologics.com\/fr\/2025\/10\/07\/gensight-biologics-publie-sa-situation-de-tresorerie-au-30-septembre-2025\/","title":{"rendered":"GenSight Biologics publie sa situation de tr\u00e9sorerie au 30 septembre 2025"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Paris, France, le 7 octobre 2025, 18h00 CEST<\/strong> \u2013 GenSight Biologics (<strong>\u00ab\u00a0GenSight Biologics\u00a0\u00bb <\/strong>ou la <strong>\u00ab Soci\u00e9t\u00e9 \u00bb<\/strong>) (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), une soci\u00e9t\u00e9 biopharmaceutique sp\u00e9cialis\u00e9e dans le d\u00e9veloppement et la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour les maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et les troubles du syst\u00e8me nerveux central, publie aujourd\u2019hui sa situation de tr\u00e9sorerie au 30 septembre 2025.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Situation de tr\u00e9sorerie et perspectives<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">La tr\u00e9sorerie et les \u00e9quivalents de tr\u00e9sorerie de GenSight Biologics s\u2019\u00e9levaient \u00e0 0,6 million d\u2019euros au 30 septembre 2025, contre 0,3 million d\u2019euros au 30 juin 2025.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Le 1er octobre 2025, la Soci\u00e9t\u00e9 a re\u00e7u le produit net de la lev\u00e9e de fonds r\u00e9alis\u00e9e le 26 septembre 2025, pour un total de 3,0 millions d\u2019euros, net du remboursement de 0,7 million d\u2019euros de principal sur les obligations convertibles d\u00e9tenues par Heights Capital. Au 1er octobre 2025, la tr\u00e9sorerie et les \u00e9quivalents de tr\u00e9sorerie de GenSight Biologics s\u2019\u00e9levaient \u00e0 3,6 millions d\u2019euros.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">La Soci\u00e9t\u00e9 dispose d\u2019un horizon de tr\u00e9sorerie suffisant pour faire face \u00e0 ses obligations jusqu\u2019\u00e0 la fin du quatri\u00e8me trimestre 2025. Toutefois, celui-ci pourrait \u00eatre prolong\u00e9 jusqu\u2019\u00e0 fin mai 2026 si une d\u00e9cision r\u00e9glementaire positive intervient avant la fin de l\u2019ann\u00e9e.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Le plan de la Direction et la Strat\u00e9gie de financement pr\u00e9sent\u00e9s dans le communiqu\u00e9 de presse des \u00e9tats financiers du premier semestre 2025, publi\u00e9 le 29 septembre 2025, demeurent valides.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Informations sur le capital<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Au 1er octobre 2025, le nombre d\u2019actions ordinaires en circulation de GenSight Biologics s\u2019\u00e9levait \u00e0 174 475 604 actions.<\/p>\n","protected":false},"excerpt":{"rendered":"<ul>\n<li>La tr\u00e9sorerie s\u2019\u00e9levait \u00e0 0,6 million d\u2019euros au 30 septembre 2025\u00a0;<\/li>\n<li>Cl\u00f4ture r\u00e9ussie d\u2019une lev\u00e9e de fonds de pr\u00e8s de 3,7 millions d\u2019euros le 1er octobre 2025\u00a0;<\/li>\n<li>La tr\u00e9sorerie s\u2019\u00e9levait \u00e0 3,6 millions d\u2019euros au 1er octobre 2025.<\/li>\n<\/ul>\n","protected":false},"author":10,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[54],"tags":[],"featured-area":[],"news-topic":[],"news-type":[80],"post-year":[],"class_list":["post-4415","post","type-post","status-publish","format-standard","hentry","category-communiques-de-presse-financiers","news-type-finance"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>GenSight Biologics publie sa situation de tr\u00e9sorerie au 30 septembre 2025 - GenSight Biologics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.gensight-biologics.com\/fr\/2025\/10\/07\/gensight-biologics-publie-sa-situation-de-tresorerie-au-30-septembre-2025\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GenSight Biologics publie sa situation de tr\u00e9sorerie au 30 septembre 2025 - GenSight Biologics\" \/>\n<meta property=\"og:description\" content=\"La tr\u00e9sorerie s\u2019\u00e9levait \u00e0 0,6 million d\u2019euros au 30 septembre 2025\u00a0;  Cl\u00f4ture r\u00e9ussie d\u2019une lev\u00e9e de fonds de pr\u00e8s de 3,7 millions d\u2019euros le 1er octobre 2025\u00a0;  La tr\u00e9sorerie s\u2019\u00e9levait \u00e0 3,6 millions d\u2019euros au 1er octobre 2025.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.gensight-biologics.com\/fr\/2025\/10\/07\/gensight-biologics-publie-sa-situation-de-tresorerie-au-30-septembre-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"GenSight Biologics\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-07T20:00:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-24T04:05:39+00:00\" \/>\n<meta name=\"author\" content=\"Arthus Moulin-Fournier\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Arthus Moulin-Fournier\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2025\\\/10\\\/07\\\/gensight-biologics-publie-sa-situation-de-tresorerie-au-30-septembre-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2025\\\/10\\\/07\\\/gensight-biologics-publie-sa-situation-de-tresorerie-au-30-septembre-2025\\\/\"},\"author\":{\"name\":\"Arthus Moulin-Fournier\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/ae14918d0ec7c587d729420ef3ca5c18\"},\"headline\":\"GenSight Biologics publie sa situation de tr\u00e9sorerie au 30 septembre 2025\",\"datePublished\":\"2025-10-07T20:00:35+00:00\",\"dateModified\":\"2026-09-24T04:05:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2025\\\/10\\\/07\\\/gensight-biologics-publie-sa-situation-de-tresorerie-au-30-septembre-2025\\\/\"},\"wordCount\":274,\"articleSection\":[\"Communiqu\u00e9 de presse Financier\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2025\\\/10\\\/07\\\/gensight-biologics-publie-sa-situation-de-tresorerie-au-30-septembre-2025\\\/\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2025\\\/10\\\/07\\\/gensight-biologics-publie-sa-situation-de-tresorerie-au-30-septembre-2025\\\/\",\"name\":\"GenSight Biologics publie sa situation de tr\u00e9sorerie au 30 septembre 2025 - GenSight Biologics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\"},\"datePublished\":\"2025-10-07T20:00:35+00:00\",\"dateModified\":\"2026-09-24T04:05:39+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/ae14918d0ec7c587d729420ef3ca5c18\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2025\\\/10\\\/07\\\/gensight-biologics-publie-sa-situation-de-tresorerie-au-30-septembre-2025\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2025\\\/10\\\/07\\\/gensight-biologics-publie-sa-situation-de-tresorerie-au-30-septembre-2025\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2025\\\/10\\\/07\\\/gensight-biologics-publie-sa-situation-de-tresorerie-au-30-septembre-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/home\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GenSight Biologics publie sa situation de tr\u00e9sorerie au 30 septembre 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/\",\"name\":\"GenSight Biologics\",\"description\":\"Restoring vision while advancing gene therapy\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/ae14918d0ec7c587d729420ef3ca5c18\",\"name\":\"Arthus Moulin-Fournier\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/eace44d269d162de11a066bf28b6d0de50aec912351357046a1db52e59b9cbf9?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/eace44d269d162de11a066bf28b6d0de50aec912351357046a1db52e59b9cbf9?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/eace44d269d162de11a066bf28b6d0de50aec912351357046a1db52e59b9cbf9?s=96&d=mm&r=g\",\"caption\":\"Arthus Moulin-Fournier\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GenSight Biologics publie sa situation de tr\u00e9sorerie au 30 septembre 2025 - GenSight Biologics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.gensight-biologics.com\/fr\/2025\/10\/07\/gensight-biologics-publie-sa-situation-de-tresorerie-au-30-septembre-2025\/","og_locale":"fr_FR","og_type":"article","og_title":"GenSight Biologics publie sa situation de tr\u00e9sorerie au 30 septembre 2025 - GenSight Biologics","og_description":"La tr\u00e9sorerie s\u2019\u00e9levait \u00e0 0,6 million d\u2019euros au 30 septembre 2025\u00a0;  Cl\u00f4ture r\u00e9ussie d\u2019une lev\u00e9e de fonds de pr\u00e8s de 3,7 millions d\u2019euros le 1er octobre 2025\u00a0;  La tr\u00e9sorerie s\u2019\u00e9levait \u00e0 3,6 millions d\u2019euros au 1er octobre 2025.","og_url":"https:\/\/www.gensight-biologics.com\/fr\/2025\/10\/07\/gensight-biologics-publie-sa-situation-de-tresorerie-au-30-septembre-2025\/","og_site_name":"GenSight Biologics","article_published_time":"2025-10-07T20:00:35+00:00","article_modified_time":"2026-09-24T04:05:39+00:00","author":"Arthus Moulin-Fournier","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Arthus Moulin-Fournier","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.gensight-biologics.com\/fr\/2025\/10\/07\/gensight-biologics-publie-sa-situation-de-tresorerie-au-30-septembre-2025\/#article","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2025\/10\/07\/gensight-biologics-publie-sa-situation-de-tresorerie-au-30-septembre-2025\/"},"author":{"name":"Arthus Moulin-Fournier","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/ae14918d0ec7c587d729420ef3ca5c18"},"headline":"GenSight Biologics publie sa situation de tr\u00e9sorerie au 30 septembre 2025","datePublished":"2025-10-07T20:00:35+00:00","dateModified":"2026-09-24T04:05:39+00:00","mainEntityOfPage":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2025\/10\/07\/gensight-biologics-publie-sa-situation-de-tresorerie-au-30-septembre-2025\/"},"wordCount":274,"articleSection":["Communiqu\u00e9 de presse Financier"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.gensight-biologics.com\/fr\/2025\/10\/07\/gensight-biologics-publie-sa-situation-de-tresorerie-au-30-septembre-2025\/","url":"https:\/\/www.gensight-biologics.com\/fr\/2025\/10\/07\/gensight-biologics-publie-sa-situation-de-tresorerie-au-30-septembre-2025\/","name":"GenSight Biologics publie sa situation de tr\u00e9sorerie au 30 septembre 2025 - GenSight Biologics","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#website"},"datePublished":"2025-10-07T20:00:35+00:00","dateModified":"2026-09-24T04:05:39+00:00","author":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/ae14918d0ec7c587d729420ef3ca5c18"},"breadcrumb":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2025\/10\/07\/gensight-biologics-publie-sa-situation-de-tresorerie-au-30-septembre-2025\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.gensight-biologics.com\/fr\/2025\/10\/07\/gensight-biologics-publie-sa-situation-de-tresorerie-au-30-septembre-2025\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.gensight-biologics.com\/fr\/2025\/10\/07\/gensight-biologics-publie-sa-situation-de-tresorerie-au-30-septembre-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.gensight-biologics.com\/fr\/home\/"},{"@type":"ListItem","position":2,"name":"GenSight Biologics publie sa situation de tr\u00e9sorerie au 30 septembre 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.gensight-biologics.com\/fr\/#website","url":"https:\/\/www.gensight-biologics.com\/fr\/","name":"GenSight Biologics","description":"Restoring vision while advancing gene therapy","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.gensight-biologics.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/ae14918d0ec7c587d729420ef3ca5c18","name":"Arthus Moulin-Fournier","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/eace44d269d162de11a066bf28b6d0de50aec912351357046a1db52e59b9cbf9?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/eace44d269d162de11a066bf28b6d0de50aec912351357046a1db52e59b9cbf9?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/eace44d269d162de11a066bf28b6d0de50aec912351357046a1db52e59b9cbf9?s=96&d=mm&r=g","caption":"Arthus Moulin-Fournier"}}]}},"_links":{"self":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/4415","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/comments?post=4415"}],"version-history":[{"count":0,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/4415\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/media?parent=4415"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/categories?post=4415"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/tags?post=4415"},{"taxonomy":"featured-area","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/featured-area?post=4415"},{"taxonomy":"news-topic","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-topic?post=4415"},{"taxonomy":"news-type","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-type?post=4415"},{"taxonomy":"post-year","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/post-year?post=4415"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}